Company news

CytomX Therapeutics, Inc. news in 2023

CytomX Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

CytomX Therapeutics to Present at Upcoming November Investor Conferences

October 31, 2023

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

October 30, 2023

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

October 29, 2023

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

October 17, 2023

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

August 9, 2023

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

July 31, 2023

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

July 16, 2023

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

June 29, 2023

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

April 30, 2023

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 24, 2023

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

March 26, 2023

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

March 21, 2023

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

January 25, 2023

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

January 16, 2023

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

January 4, 2023

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 4, 2023

Calls in 2023

Decks in 2023